Please use this identifier to cite or link to this item:
Title: New pharmacological approaches to the management of depression: from theory to clinical practice.
Austin Authors: Norman, Trevor R ;Judd, F K;Burrows, Graham D
Affiliation: Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria.
Issue Date: 1-Mar-1992
Publication information: The Australian and New Zealand Journal of Psychiatry; 26(1): 73-81
Abstract: A review of the clinical efficacy of four structurally distinct antidepressant drugs is presented. Their antidepressant activity can be rationalised within current pharmacological hypotheses of drug action, despite markedly different effects on "in vitro" testing. Fluoxetine, a specific serotonin re-uptake inhibitor, has proven safe, effective treatment for depressive illness and may have a role to play in the treatment of obsessive-compulsive disorder and panic attacks. While it has few of the anticholinergic side effects of the tricyclic antidepressants, nausea, tremor, headache, weight loss, nervousness and sweating are side effects most frequently reported. Minaprine, a compound with weak MAO inhibiting properties and effects on serotonergic receptors, has clinical efficacy in the treatment of depression based on several comparative studies. It is claimed that minaprine lacks anticholinergic and sedative properties. Moclobemide, a specific, reversible inhibitor of MAO-A, has been extensively evaluated in depressive illness. The major advantage of this agent over other irreversible, non-specific MAO inhibitors, is the significant attenuation of the so-called "cheese effect" with doses of tyramine likely to be encountered in foodstuffs. Rolipram, a phosphodiesterase inhibitor, represents a new approach to antidepressant treatment. Limited clinical data suggest that the drug may be an effective antidepressant with few side effects. The place of these agents in therapy is yet to be established.
Gov't Doc #: 1580888
Type: Journal Article
Subjects: Antidepressive Agents.adverse effects.therapeutic use
Benzamides.adverse effects.therapeutic use
Depressive Disorder.drug therapy.psychology
Fluoxetine.adverse effects.therapeutic use
Pyridazines.adverse effects.therapeutic use
Pyrrolidinones.adverse effects.therapeutic use
Second Messenger Systems.drug effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.